Alymsys® (bevacizumab-maly), a biosimilar to Avastin® (bevacizumab), has been made available by Amneal Pharmaceuticals.
Alymsys is a VEGF inhibitor approved for the treatment of metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment or in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen.
Alymsys is also approved to treat recurrent glioblastoma in adults; metastatic renal cell carcinoma, in combination with interferon alfa; and unresectable, locally advanced, recurrent or metastatic nonsquamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment.
The drug is also approved to treat gynecologic cancers, including persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan; and epithelial ovarian, fallopian tube, or primary peritoneal cancer, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for patients with platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens.
Alymsys is not indicated for adjuvant treatment of colon cancer. Lack of efficacy of bevacizumab as an adjunct to standard chemotherapy for the adjuvant treatment of colon cancer was determined in 2 randomized, open-label, multicenter clinical studies.
Alymsys is supplied in single-dose vials containing 100 mg/4 mL and 400 mg/16 mL of bevacizumab-maly.
Amneal launches first biosimilar with Alymsys® (bevacizumab-maly) in the United States. News release. Company. Accessed October 4, 2022. https://www.businesswire.com/news/home/20221003005346/en/Amneal-Launches-First-Biosimilar-with-ALYMSYS%C2%AE-bevacizumab-maly-in-the-United-States
This article originally appeared on MPR